TGF-β inhibitors for the treatment of cancer

被引：66

作者：

Lahn, M ^{[1
]}

Kloeker, S ^{[1
]}

Berry, BS ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Therapeut Area Oncol, Indianapolis, IN 46285 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 06期

关键词：

antisense oligonucleotide; cancer; clinical Studies; knockout mice; monoclonal antibodies; TGF-beta; TGF-beta RI kinase inhibitors;

D O I：

10.1517/13543784.14.6.629

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small molecules. in this review, the current stage of development of each known TGF-beta inhibitor will be discussed. As part of the risk/benefit assessment of TGF-beta inhibitors, the known effects of TGF-beta deficiency in mice, non-clinical toxicology studies with TGF-beta inhibitors in rats, and the clinical studies with monoclonal antibodies against TGF-beta will be summarised.

引用

页码：629 / 641

页数：13

共 124 条

[1]

Abrams SI, 2004, CURR OPIN MOL THER, V6, P71

[2] LOCALIZED PRODUCTION OF TGF-BETA MESSENGER-RNA IN TUMOR PROMOTER-STIMULATED MOUSE EPIDERMIS [J].

AKHURST, RJ ;

FEE, F ;

BALMAIN, A .

NATURE, 1988, 331 (6154) :363-365

[3] Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response [J].

Ashcroft, GS ;

Yang, X ;

Glick, AB ;

Weinstein, M ;

Letterio, JJ ;

Mizel, DE ;

Anzano, M ;

Greenwell-Wild, T ;

Wahl, SM ;

Deng, CX ;

Roberts, AB .

NATURE CELL BIOLOGY, 1999, 1 (05) :260-266

[4] Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration [J].

Bakin, AV ;

Tomlinson, AK ;

Bhowmick, NA ;

Moses, HL ;

Arteaga, CL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (47) :36803-36810

[5]

Bakin AV, 2002, J CELL SCI, V115, P3193

[6] Future options with trastuzumab for primary systemic and adjuvant therapy [J].

Baselga, J ;

Gianni, L ;

Geyer, C ;

Perez, EA ;

Riva, A ;

Jackisch, C .

SEMINARS IN ONCOLOGY, 2004, 31 (05) :51-57

[7]

Berking C, 2001, CANCER RES, V61, P8306

[8] Stromal fibroblasts in cancer initiation and progression [J].

Bhowmick, NA ;

Neilson, EG ;

Moses, HL .

NATURE, 2004, 432 (7015) :332-337

[9] Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism [J].

Bhowmick, NA ;

Ghiassi, M ;

Bakin, A ;

Aakre, M ;

Lundquist, CA ;

Engel, ME ;

Arteaga, CL ;

Moses, HL .

MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (01) :27-36

[10]

BOGDAHN U, 2004, 40 ASCO ANN M NEW OR, P4514

← 1 2 3 4 5 6 7 8 9 10 →